Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

Kansas’ Jerry Moran is part of a bipartisan group of U.S. senators working to reduce large hospital networks’ fraud and abuse ...

FAH rebuts Senate hearing claims, clarifying taxpaying hospitals do not benefit from the 340B drug pricing program discounts.

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

If drugmakers have their way, the federal government likely ends up spending $100 billion of taxpayer funds to bail out rural hospitals.

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...

The Health Resources and Services Administration ("HRSA") plans to implement a limited pilot program that will allow approved manufacturers to issue post-purchase rebates for 340B covered outpatient ...

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

A discount drug program is being abused by large hospital chains in Chicago leaving communities on the South and West sides ...

On August 6, 2025, the U.S. Court of Appeals for the Second Circuit issued an opinion allowing a case challenging drug pricing changes to proceed. The case, an antitrust action brought by health ...